Key Takeaways Stem cell therapy for anoxic brain injury is still experimental, and no study has compared early with late treatment in people. Most natural recovery after cardiac arrest occurs in the first three months, a 2017 study of 141 survivors found. Cooling newborns within six hours reduces death and
Key Takeaways Stem cells for psoriasis remain experimental, and the human evidence comes from very small studies. Cochrane’s living review found that biologic medicines cleared skin better than older tablets across 204 studies. A 2022 trial of 17 people found 8 had at least 40% skin improvement after cord cell
Key Takeaways A Japanese health ministry panel backed full approval of Stemirac, a bone marrow cell therapy, on 15 October 2026. Reported data compared 73 treated patients with 66 untreated patients, and 40 treated patients improved in motor function. Treated patients received more rehabilitation, so it’s hard to isolate the
Key Takeaways Stem cell therapy for cerebral palsy is still experimental and is not established standard care. A 2021 randomized trial of 72 children reported higher motor scores 12 months after cord tissue cells than after a pretend procedure. Two 2025 reviews found average gains of about 1 to 1.5
Key Takeaways Mesenchymal stem cells are among the most studied cell types for chronic liver disease, but the approach is still experimental. Researchers think the cells may calm the immune system and slow scar-forming cells, mostly based on lab and animal work. Small human trials reported better survival in some
Key Takeaways A phase 2b trial gave 148 adults aged 70 to 85 one infusion of donated mesenchymal stem cells or placebo. At nine months, the 200 million cell group walked 63.4 meters farther than placebo. The six-month gap of 41.3 meters did not reach statistical significance. A second open-label
Key Takeaways Stem cell therapies for kidney disease are still experimental, and a 2025 review found lower inflammation markers in animals but no clear change in people. That review pooled 49 animal studies and only three small human trials involving 86 people. Standard care, such as blood pressure control, remains
Key Takeaways Researchers test stem cell therapies for heart failure, but no trial shows that the cells rebuild a damaged heart. A 2016 Cochrane review of 38 trials and 1,907 people found no gain in heart pumping strength and rated the evidence low quality. A 2012 trial of 30 people
Key Takeaways Mesenchymal stem cells (MSCs) have been tested in small rheumatoid arthritis (RA) trials, but no trial shows they stop the disease for good. A 2019 study of 64 people with RA reported lower disease scores at one and three years after umbilical cord cell infusion. A 2017 placebo-controlled
Key Takeaways Mesenchymal stem cell (MSC) therapy has been tested in small human trials for chronic lung inflammation, but none show it reverses lung scarring. A 2013 randomized trial of 62 people with chronic obstructive pulmonary disease (COPD) found no lung function gain from infused MSCs. A 2020 randomized trial
